在治疗青光眼和青光眼手术中使用罗基纳斯抑制剂 (ROCK):对早期到晚期临床试验的系统审查
Jit Kai Tan1,2, Peng Tee Khaw3, Christin Henein3
1Guy's Campus, King's College London, London SE1 1UL, UK.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
罗基纳酶 (ROCK) 抑制剂在治疗初级开角青光眼 (POAG) 中是安全有效的,与当前治疗方法相比,其表现不逊色. 需要进一步的研究来优化它们的使用,并了解长期益处.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 主要开角青光眼 (POAG) 是不可逆转的视力丧失的主要原因.
- 前列腺素类似物是标准的第一线POAG治疗,但正在研究新型疗法.
- 罗基纳酶 (ROCK) 抑制剂代表了一种用于治疗青光眼的新药类.
研究的目的:
- 审查ROCK抑制剂在POAG治疗中的有效性和安全性.
- 为了将ROCK抑制剂试验结果与自然历史数据进行比较.
- 确定POAG中ROCK抑制剂治疗的研究缺口.
主要方法:
- 在Ovid MEDLINE和Embase数据库的系统文献搜索.
- 这些关键词包括"眼","rho激酶抑制剂"",ripasudil"",netarsudil"和"fasudil".
- 相关研究摘要进行了选,结果进行了表化.
主要成果:
- ROCK 抑制剂对POAG是安全有效的,表明对现有治疗方法的不劣.
- 当ROCK抑制剂作为组合疗法使用时,它们显示出有效性.
- 由于局限性,与自然历史研究的数据比较是不确定的.
结论:
- ROCK 抑制剂具有良好的安全性,并有效降低眼内压力.
- 最佳剂量,患者选择和成本效益需要进一步研究.
- 大规模的前性随机对照试验是必要的,以确认长期的价值和安全性.
相关概念视频
Small GTPases - Ras and Rho
3.8K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.8K
Glaucoma: Overview
470
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
470
Open Angle Glaucoma: Treatment
358
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
358
Angle Closure Glaucoma: Treatment
374
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
374
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
99
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
99
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
91
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
91


